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CHAPTER 1
Introduction
Dena J.P. Gamer
Department of Exercise and Sport ScienceMultiple sclerosis
In the United States there are between 200,000350,000 persons with
multiple sclerosis (MS). The risk of developing MS in the United States is 1 in
1000 with two-third's being women who are in their late twenties and early thirties
(Joy et al. 2001). MS is more common in people with northern European heritage,
affecting 200 in 100,000 people from this region (Kurtzke 1985). Studies have also
shown that there is an increased prevalence of MS in those who live in higher
latitudes during childhood, whereas, MS is virtually non-existent in populations
around the equator (Kurtzke 1985). The increased prevalence of MS in the
moderate to colder climates has been attributed to genetic and environmental
factors, yet no causal relationship has been established between the disease and
these factors (Martin et al. 1997).
Pathophysioloy of multiple sclerosis
Although the exact cause of MS has not been determined, it is generally
believed to be an autoimmune disease. Normally the brain is protected from
foreign bodies and toxins by the blood brain barrier. However, during MS, blood-
borne immune cells cross the blood brain barrier and destroy the myelin sheath,
resulting in inflammation and lesion formation. The attack of the myelin sheath
leads to the formation of active or chronic lesions, or plaques, which are typically
located within the central nervous system. Active lesions suggestan area of active
inflammation and therefore progressive demyelination, whereas chronic lesionsareconsidered dormant with no signs of active inflammation (Hailpike 1983;Whitaker
etal. 1997; Joy etal. 2001; National MS Society, October 1997).
The destruction of the myelin sheath resu!ts in themany symptoms
associated with MS. Myelin is a fatty substance that insulatesaxons and increases
the speed of action potentials. If mye!in is destroyed, action potentia!s betweenand
within the central and peripheral nervous systems will be slowedor halted. The
s!owing or halting of action potentials causes many of the primary, secondary, and
tertiary symptoms associated with MS (McAlpine et al. 1972; Hal!pike 1983;
Whitaker et al. 1997; Joy etal. 2001).
Primary symptoms of MS are directly related to demye!ination and include
weakness, fatigue, walking difficu!ties, pain, numbness, and spasticity. Secondary
symptoms occur due to comp!ications and recurrences of the primary symptoms.
Secondary symptoms inc!ude urinary tract itifections from repeated b!adder
dysfunction, and physical inactivity due to increased fatigue and weakness. The
tertiary symptoms are a consequence of the primary and secondary symptoms and
are most often related to psycho!ogical and vocational issues. A tertiary symptom
may be depression which can result from the !oss ofajob, inability to ambulate,
and the ineffectiveness to complete activities of dai!y living (McAlpine et al. 1972;
Halipike 1983; Joy et al. 2001; Nationa! MS Society, October 1997)
Impairments in musc!e function, which include muscle fatigue and
weakness, are predominant symptoms of MS (Joy et al. 2001). Fatigue has been
cited as the most prevalent and debilitating symptom of MS, affecting 75-85% of4
individuals with MS (Freal et al. 1984; Krupp et al. 1988). Muscle weakness has
been cited as affecting 80% of persons with MS (Matthews 1998). Fatigue and
weakness in MS affects activities of daily living, making it harder to complete
common tasks, such as brushing teeth or making a bed, maintaining physical
activity, and meeting daily responsibilities (Krupp et al. 1988; Vercoulen et al.
1996).
Muscle weakness in multiple sclerosis
Researchers have cited that persons with MS, on average, are 25-40%
weaker than subjects without MS (Rice et al. 1992; Kent-Braun et al. 1994; Sharma
et al. 1995; Schwid et al. 1999; Lambert et al. 2001). Rice and colleagues (Rice Ct
al. 1992) studied the extent of muscle weakness in MS by examining maximal
voluntary contractions (MYCs) in subjects with and without MS. They found that
the MVCs of the quadriceps from all their subjects with MS ranged from 40-70%
below mean normal values. de Haan et al. (de Haan et al. 2000) obtained similar
results, in which they found that the average MVCs of the quadriceps inpersons
with MS were 31% lower than the MVCs of persons without MS. Other studies
involving the lower limbs have found that knee extensor strength, knee flexor
strength, and the anterior tibialis strength of persons with MS was 26-38% lower
than that of controls (Kent-Braun et al. 1994; Sharma et al. 1995; Schwid et al.
1999; Lambert et al. 2001).To determine how much of that weakness in MS could be contributedto
deficits within the muscle, studies have bypassed centralnervous mechanisms by
using electrical stimulation protocols (Rice et al. 1992; Kent-Braunet al. 1994;
Sharma Ct al. 1995). Electrical stimulationmeasures the intrinsic force that muscle
can produce without the influence of central factors such as motivation or motor
unit recruitment (Kent-Braun 1997). Rice et al. (Rice et al. 1992) compared force
produced during electrical stimulation to that of the subject's MVC and found that
approximately 50% of muscle weakness in persons with MSwas due to peripheral
deficits, while 50% was due to central mechanisms of fatigue. Sharrna et al.
(Sharma et al. 1995) attributed 65% of the muscle weakness to peripheral deficits,
while Kent-Braun et al. (Kent-Braun et al. 1994) found even greater deficits in
peripheral mechanisms that contribute to muscle weakness in MS. These studies
reveal that part of the muscle weakness in MS is due to deficits within the central
nervous mechanisms such as decreased ability to excite motor neurons, but
between one-half to two-thirds of muscle weakness can be attributed to deficits
within the peripheral nervous system (Rice et al. 1992; Kent-Braun et al. 1994;
Sharmaetal. 1995).
Mechanisms of muscle contraction
The peripheral mechanisms of muscle weakness are related to the function
of muscle cells, or fibers, which comprise the whole muscle. A single muscle fiber
is made of numerous myofibrils which are parallel bundles containing repeatingunits of sarcomeres. A Z line, or a Z disk, binds eachsarcomere at its end.
Between the Z lines of one sarcomere are interdigitating proteins called thick and
thin filaments. The thin filament is comprised mostly of the protein actin,whereas
the thick filament consists of mostly myosin. The interaction of actin andmyo sin
is the basis of the cross-bridge mechanisms of contraction (Huxley 1974).
The initiation of muscle contraction depends on the neural activation of the
muscle cell. Action potentials from the central nervous system (CNS), involving
the brain and the spinal cord, travel to the muscle via alpha-motorneurons. Alpha-
motor neurons have long projections from the neuron called axons, which are
protected by a myelin sheath, a lipid substance that increases the conductivity of
the action potentials (Waxman 1998). To transmit the action potential from the
alpha-motor neuron to the muscle cell, the action potential must cross a synaptic
cleft, an area separating the motor neuron and the muscle cell it innervates. For this
transmission to occur synaptic vesicles on the alpha-motor neuron release the
neurotransmitter acetyicholine (ACh), which will bind to receptors on the motor
end plate of the muscle cell causing a depolarization of the muscle cell (Gandevia
2001).
Excitation-contraction coupling
The processes by which the depolarization of the muscle cell leads to
muscle contraction are termed excitation-contraction coupling (ECC). When the
muscle is depolarized, the action potential travels down the cell membrane and into7
invaginations of the muscle cell called t-tubules. Depolarized t-tubules will
activate the sarcoplasmic reticulum (SR) to release calcium (Ca2). The
mechanisms by which the depolarization oft-tubules cause the SRto releaseCa2
are still not entirely clear. Chandler et al. (Chandler et al. 1976) suggests that there
is a mechanical linkage between the t-tubules and the SR. The dihydropyridine
receptors (DHPR), which serve as "charge sensors" on the t-tubules, are
mechanically linked to the ryanodine receptors (RyR) on the SR. which functionas
Ca2release channels. A depolarization of the t-tubules will cause a
conlormational change in the DHPR, which is transmitted over a mechanical
linkage, "unplugging" the RyR and allowingCa2to leave the SR and initiate
muscle contraction.
Cross-bridge cycle
The release ofCa2from the SR enables the myosin heads of the thick
filament to strongly bind with actin, termed an actomyosin cross-bridge. Strongly
bound cross-bridges may undergo cycles of detachment and re-attachment. Each
cross-bridge cycle is associated with a power stroke, whereby myosin pulls actin
towards the center of the sarcomere producing force and shortening thesarcomere.
The cross-bridge cycle depends on the presence of adenosine triphosphate (ATP),
which comes from anaerobic and aerobic metabolism. ATP attaches to the
actomyosin cross-bridge and quickly dissociates the actin from the myosin. ATP
remains attached to the myo sin but quickly hydrolyzes into adenosine diphosphate8
(ADP) and inorganic phosphate (P1). The myosin-ADP-P1 complex reattaches itself
to actin and forms a weak bond. P release is associated with the actomyosin
complex undergoing a transition from a weakly bound, low force producingstate to
a strongly bound, force producing state. After the power stroke, ADP is released
resulting in a rigor cross-bridge. The cross-bridge is now set for another round of
the cycle (Cooke 1997).
Muscle fiber types
Muscle fibers within a given muscle express a specific myosin heavy chain
isoform (M}IC). In human muscle there are three basic MIlIC isoforms, type I, ha,
and lix isoforms, with hybrids of these fiber types that include type hIlla and IIaJIIx
isoforms. While muscle fibers, regardless of their MHC isoform, undergo similar
cross-bridge mechanisms of contraction, each MHC isoform is associated with
variations in the amount of force, shortening velocity and power produced during
cross-bridge cycling (Moss et al. 1995).
Differences in force between the MHC isoforms are due to the amount of
mitochondria present in the fiber. Type I fibers contain increased concentrations of
mitochondria causing this fiber type to be the most oxidative and therefore least
fatigue-resistant of any fiber type. However, with increased mitochondria in the
muscle fiber there is less room for actin and myosin cross-bridge cycling, resulting
in lower force production of the type I fibers. Type ha and lix have lesser amounts
of mitochondria, with lix having the least amount of mitochondria, leading toanincreased number of cross-bridge formations, and therefore, greater force
production (Tikunov et al. 2001).
MHC isoforms also exhibit different rates of cross-bridge cycling, withthe
rate of cross-bridge cycling correlated to shortening velocity. Studies have shown
that the type I MHC isoform has the lowest shortening velocity, while the type ha
and lix have faster shortening velocities than the type I fibers, with the MHCtype
lix exhibiting the fastest shortening velocity (Fitts 1994). Due to differences in
shortening velocity, type I MHC isoforms are typically categorizedas slow fiber
types, while type ha and lix MHC isoforms are labeled as fast fiber types.
Mechanisms of muscle weakness in multiple sclerosis
Rice et al. (Rice et al. 1992), Kent-Braun et al. (Kent-Braun et al. 1994),
and Shanna et al. (Sharma et al. 1995) attributed part of the muscle weakness in
MS to deficits within the muscle cell resulting from muscle disuse and de-
conditioning. Studies have shown that persons with MS are significantly less
active than persons without MS (Kent-Braun et al. 1997; Ng et al. 1997;
Stuifbergen 1997). Stuifbergen (Stuitbergen 1997) correlated maximal activity
score and adjusted activity scores of subjects with MS and found a 26% difference
between maximal and adjusted activity scores. This indicates that the average
physical activity level in persons with MS was significantly lower than the
maximal level of healthy controls. Studies using accelerometers, an instrument that
directly measures physical activity by recording motion as body acceleration,10
reveals that subjects with MS are 37% less active than controls (Kent-Braunet al.
1997; Ng et al. 1997).
Extreme levels of physical inactivity, termed models of disuse,may help
explain the muscle weakness experienced by persons with MS. Models of disuse,
which include both short-term models such as spaceflight and bed-rest and long-
term models such as spinal cord injury, have found significant changes in muscle
cell function and composition. Such changes include reductions in thecross-
sectional area (CSA) of fibers, decreases in absolute and specific fiber force (P0) of
the fiber, and a decreased percentage of type I fibers and an increase in type II
fibers.
Short-term and long-term disuse studies reveal that while there is atrophy of
all fiber types, there is selective atrophy of type II fibers. After 17 days of
spaceflight, Widrick et al. found a 26% reduction in CSA of the type ha fibers with
a 15% reduction of the CSA of the type I fibers (Widrick et al. 1999). Castro et al.
(Castro et al. 1999) found that six weeks post spinal cord injury resulted ina 40%
reduction of CSA of the type ha and hlax + lix fibers versus a 31% reduction of
CSA of the type I fibers. In a study that assessed CSA of muscle samples from
subjects with MS, Kent-Braun et al. (Kent-Braun et al. 1997) found that therewas a
25% reduction of CSA of type I fibers from the tibialis anterior in subjects with MS
and a 31-36% reduction of CSA of type ha and hlax fibers. These results reveal
greater atrophy of the type II fibers in subjects with MS, with atrophy of both fiber11
types exceeding the atrophy noted in short-term disuse and approaching atrophy
seen in 6-week post spinal cord injury.
Short-term disuse also affects changes in the absolute force, total force that
a fiber can produce, and specific force, force per CSA of a muscle fiber. Widrick Ct
al. (Widrick et al. 1999) found a 21% reduction in absolute force of type I fibers
after 17 days of spaceflight, while bed-rest revealed that absolute force in type I
fibers dropped 13% after 17 days of disuse (Widrick et al. 1997). Short-term
disuse also reveals that the specific force of type I fibers is 6% lower after 17 days
of spaceflight (Widrick et al. 1999). Decreases in absolute force can be attributed
to decreases in CSA of the fiber. Absolute force is related to the number of cross-
bridge formations; a smaller fiber will have fewer cross-bridges, resulting in
decreased force production. Specific force accounts for the CSA of the fiber, thus
decreases in specific force are attributed to deficits at the level of the cross-bridge.
Deficits at the level of the cross-bridge may include shifts from high force-
producing states to low force-producing states, thereby reducing the average force
per cross-bridge.
Musck fatigue
Physiological fatigue has been defined as the inability to sustain the
required or expected force (Fitts 1994). The identification of fatigue can bea
complex issue due to the various factors that elicit the fatigue response in
individuals. These factors include the type, duration, and intensity of the activity,12
the training status of the individual, and muscle fiber recruitment during the activity
(Fitts 1994). The physiological causes of muscle fatigue can occur within the
central and peripheral nervous system. These sites within the centralnervous
system include: 1) supraspinal failure, 2) segmental afferent inhibition, 3)
depression of motor neuron excitability, 4) loss of excitation at branch points, 5)
pre-synaptic failure, and 6) inability to transmit an action potential from the
neuromuscular junction. Within the peripheral nervous system fatigue canoccur
due to: 1) failure of the muscle membrane to sustain the action potential, 2) loss of
coupling between the t-tubules and the sarcoplasmic reticulum, 3) depressedCa2
release from the sarcoplasmic reticulum, 4) reduced binding affinity ofCa2to
troponin, 5) failure of the cross-bridge cycle, 6) delayed cross-bridge dissociation,
and 7) depressed re-accumulation of theCa2into the sarcoplasmic reticulum. A
failure at any one of these central or peripheral areaswillcontribute to muscular
fatigue (Green 1987; Westerblad et al. 1991; Fitts 1994; Gandevia 2001).
A distinction between peripheral and central fatigue can be made during a
fatiguing protocol by comparing voluntary contractions to electrical stimulation of
the muscle group or by interposing twitch stimulation to a voluntary contraction
(Gibson et al. 1985). Studies have shown that in well-motivated subjects, there is
little indication that central mechanisms contribute to fatigue, rendering peripheral
mechanisms the most likely source of fatigue (Merton 1954; Bigland-Ritchie etal.
1978). In a classic fatigue study, Merton (Merton 1954) asked subjects to
maximally contract the adductor pollicis until the muscle fatigued. With the onset13
of fatigue all central mechanisms were bypassed by electrically stimulating the
ulnar nerve, a nerve that stimulates the adductor pollicis. Subjectswere also asked
to complete a maximal voluntary contraction after fatigue. Merton found that the
muscle contractions with electrical stimulation and the voluntary maximal
contractions were similar, concluding that fatigue was due to deficits within the
peripheral nervous system.
Muscle fatigue in multiple sclerosis
Since MS is considered a disease of the central nervous system, researchers
have focused on central nervous system mechanisms of fatigue as the most
probable cause for the muscle fatigue in those with MS. Studies which involve
upper limb muscle groups such as bilateral biceps, adductor pollicis, and flexor
carpi radialis have shown that muscle fatigue in these groups was due solely to
deficits within the central nervous system (van der Kamp et al. 1991; Djaldetti etal.
1996; Sheean et al. 1997; Petajan et al. 2000; de Ruiter et al. 2001). These studies
attributed muscle fatigue to increases in central motor conduction time, decreases in
motor unit firing rates, and decreases in motor unit recruitment.
Not all of the muscle fatigue in MS can be explained by deficits within the
central nervous system. In studies which involve lower limbs, suchas the
quadriceps and anide dorsiflexors, muscle fatigue is partially due to peripheral
nervous system deficits (Lenman et al. 1989; Rice et al. 1992; Kent-Braun et al.
1994; Sharma et al. 1995). A study by de Haan and colleagues (de Haan et al.14
2000) involved electrically stimulating the quadriceps of subjects with and without
MS during a fatiguing protocol. When compared to initial, pre-fatigue force
values, the subjects with MS showed significant reduction, 31%, in force after
fatigue, whereas, the controls had a smaller reduction, 24%, in force values after
fatigue. Sharma et al. (Sharma et al. 1995) found similar results duringa fatiguing
protocol involving the anterior tibialis of subjects with and without MS. Therewas
a 35% and 14% reduction in force after fatigue as compared to initial force values
in subjects with and without MS, respectively.In addition, Sharma and colleagues
saw no impairments in compound muscle action potential, a measure of action
potential propagation from the neuromuscular junction, in subjects with MS before
and after the exercise protocol. This would suggest that therewere no impairments
of action potential propagations from the central nervous mechanisms to the muscle
during and after exercise.
Studies have also shown that the recovery of force after fatigue is
significantly prolonged in subjects with MS versus controls (Kent-Braun et al.
1994; Sharma et al. 1995). Results from Kent-Braun et al. (Kent-Braun et al. 1994)
reveal that tetanic relaxation both pre- and post-exercise was 35% and 20%,
respectively, longer than tetanic relaxation of controls at baseline. Shanna et al.
also found that tetanicV2relaxation time after electrically stimulated exercise was
30% longer in subjects with MS versus controls. The delayed force recovery after
exercise suggests impairments within the muscle, specifically at the level of
excitation contraction coupling.15
Mechanisms of muscle fatigue
Using skinned fiber preparations, researchers have isolated cross-bridge
mechanisms of contraction without the influence of excitation-contractioncoupling
mechanisms. This preparation allows researchers to manipulate the cellular
environment to mimic biochemical conditions that occur during muscle fatigue. As
fatigue occurs in skeletal muscle, metabolic changes occur in the muscle, resulting
in a depression of force. These metabolic changes include: 1) an increase
accumulation of P1due to the breakdown of creatine phosphate and 2) lactic acid
accumulation, which results in an increase of hydrogen ions and depressed pH
(Fitts 1994; Westerbiad et al. 2002). During the cross-bridge cycle, ADP and
P1are
split from ATP. P1is then released from ADP, resulting in ADP and P1
accumulation in the muscle. Though there is an accumulation of ADP, it has been
shown to have minor effects on muscle, whereas, accumulation of
P1has major
effects on muscle function (Fitts 1994). This increased accumulation ofP1keeps
more cross-bridges in a weakly bound state, reducing the number of strongly bound
force producing cross-bridges, and thereby reducing the force a fibercan produce
(Fitts 1994; Westerbiad et al. 2002). During fatigue lactic acid also accumulates
and itwilldissociate into lactate and hydrogen ions. It is the increase of hydrogen
ions which is believed to affect force either by interfering with actomyosincross-
bridge cycling, resulting in a decreased number of cross-bridge formations andlor
by a decreased sensitivity of troponin for calcium and an increased sensitivity to16
hydrogen ions, thereby, decreasing the force per cross-bridge (Fabiato et al. 1978;
Metzger et al. 1987; Renaud et al. 1987; Metzger et al. 1990; Fitts 1994).
During rest, intramuscularP1values are estimated to be between 1-6 mM,
with intramuscular values ofP1exceeding 30 mM during fatigue (Cady et al. 1989).
Studies have shown that this increased accumulation ofP1during fatigue has
differential effects on fibers expressing slow or fast MHC isoforms (Nosek et al.
1990; Stienen et al. 1992; Fryer et al. 1995; Potma et al. 1995; Widrick 2002).
However, it is debatable whether increased concentrations ofP1affect fast or slow
fibers to a greater or lesser extent. Stienen and colleagues (Stienen et al. 1992)
found that the force of rabbit psoas fibers (fast fibers) was more affected by
increasedP1than were rabbit soleus fibers (slow fibers). They noted a 42%dropin
force in fast fibers and a 22% reduction in force in slow fibers at aP1concentration
of 15 mM. Potma (Potma et al. 1995) and Nosek (Nosek et al. 1990) found that
fast and slow fibers were equally sensitive to increases in P1. They found a 40-50%
reduction in force for both the fast and slow fibers at 30 mM P1. At 30 mM ofP1,
Widrick (Widrick 2002) found a 44% reduction of force in type I rat fibers and a
42% reduction of force in type lib fibers, similar to the 40-50% reduction of force
found by Potma et al. (Potma et al. 1995) and Nosek et al. (Nosek et al. 1990).
Others have found that the slow fiber types are more affected than fast fiber types
with increases in P1. Fryer et al. found a 65% and 45% reduction of force in rat
slow and fast fibers, correspondingly, at 30 mM of P, with significant differences17
in force found between slow and fast fibers atP1concentrations of 1, 5, 25, and 50
mM (Fryer et al. 1995).
In the muscle cells, resting pH values are approximately 7.0. With fatiguing
exercise pH values drop to pH 6.5, with this drop in pH being proportionalto
increased accumulation of hydrogen ions (Cady et al. 1989). Studies have also
shown that changes in pH, i.e. increased accumulation of hydrogen ions, have
different effects on the force of fast and slow MHC fiber types. With decreasing
pH, the decline of force in fast fibers appears to be greater than the decline of force
in slow fibers (Donaldson et al. 1978; Metzger et al. 1987; Chase et al. 1988;
Lynch et al. 1994; Potma et al. 1994).
Studying rabbit adductor magnus, a fast-twitch skeletal muscle, and the
rabbit soleus, a slow-twitch skeletal muscle, Donaldson and Hermansen
(Donaldson et al. 1978) and Chase et al. (Chase et al. 1988) found that the force of
the soleus fibers was generally unaffected by a decrease in pFI, whereas, the force
of the adductor magnus fibers was significantly depressed with a decrease in pH.
Chase et al. (Chase et al. 1988) found when pH was decreased from 7.1 to 6.0, the
force of psoas fibers was reduced by 50%. This was a greater reduction in forceas
compared to the 35% reduction in force of the soleus fibers that occurred with the
same changes in pH. Donaldson and Hermansen (Donaldson et al. 1978) found
that fast fibers in the rabbit had a 30%dropin force at pH 6.5 while the slow fibers
had a 12% drop in force at pH 6.5. In rats, when pH was decreased from 7.0 to 6.2
the force of slow twitch soleus muscles was reduced 27%, while therewas a 35%18
reduction of force in the fast twitch superficial and deepvastus lateralis muscles
with the same changes in pH (Metzger et al. 1987). Inone known human study,
Lynch et al. (Lynch et al. 1994) found that changes in pH from7.1 to 6.6 resulted
in 7% force reduction in the type I fibers of the vastus lateralisand a 18-21%
reduction in force of the type ha and lix fibers with thesame changes in pH.
Hence, both animal and human studies have shown that with decreases inpH the
force of fast fiber types is affected significantlymore than the force of slow fiber
types.
Mechanisms of increased fatigability in multiple sclerosis
Studies have shown that there is increased muscle fatigue inpersons with
MS that cannot be solely explained by centralnervous system deficits (Kent-Braun
et al. 1994; Sharma et al. 1995). These studies have indicated that impainnents
within the muscle cell are responsible for part of the muscle fatigue inpersons with
MS. Deficits within the muscle may be partially explained by the exaggerated
response of metabolites, specifically inorganic phosphate(P1), and hydrogen ions
(pH), in subjects with MS. Sharma et al. (Sharma et al. 1995) found that aftera
fatigue protocol there was a 42% increased accumulation of P witha 2% decrease
in pH in subjects with MS versus controls. Basedon the data in this study, Sharma
and colleagues concluded that part of the fatigue in subjects with MScould be
attributed to a greater accumulation of metabolites.19
Shifts in myosin heavy chain isoforms from type I MHC totype II MHC
may also explain increased fatigability in individuals with MS. Studying muscle
biopsies from the tibialis anterior, Kent-Braun et al. foundan increased percentage
of faster, more fatigable fiber types in persons with MSas compared to subjects
without MS (Kent-Braun et al. 1997). Subjects with MS had 13% fewer of thetype
I oxidative fibers and 22-32% more type ha and Ilax fibersversus controls.
These findings with isoform shifts in MS are comparable to isoform shifts
during short-term and long-term disuse model studies. After spaceflight, studies
have also shown there is as much as a 12% decrease in the number of type I fibers
and a 9% increase in the number of the faster, more glycolytic type ha fibers
(Thomason et al. 1990; Edgerton et al. 1995; Widrick et al. 1998; Widrick et al.
1999; Fitts et al. 2000). An analysis of 24-week post-spinal cord injury showedno
changes in type I fibers, but there was a 56% reduction of type ha fibers anda 27%
increase in the type Ilax + lix fibers as compared to fiber type percentages at 6-
weeks post-spinal cord injury (Castro et al. 1999). Thus, the shifts of MHC
isoforms in MS are slightly greater than shifts seen in short-term disuse but notas
great as those seen in spinal cord injury.
Hypothesis
Previous studies have suggested that not all of the muscle fatigue and
weakness is due to deficits within the central nervous system, butmay also be
attributed to peripheral nervous system deficits, specifically at the muscle level.20
The purpose of this project is to investigate the possible deficits withinthe muscle
that could be responsible for muscle fatigue and weakness inpersons with MS.
The hypothesis to be tested is that cross-bridge mechanisms of contractionand
fiber type content and composition in subjects with MSare responsible for part of
the muscle fatigue and weakness in this population. In order to test this hypothesis,
experiments will be performed with the following specific aims:
1.The effect of MS on cross-bridge mechanisms of contractionwillbe evaluated
by comparing the peak Ca2-activated force (P0), maximal shortening velocity
(V0), and peak power of single muscle fibers from individuals with and without
MS.
2. Whether fibers from individuals with MS are more sensitive to changes in the
metabolites will be examined by comparing the effect of the metabolites, H
and P1, onP0of single muscle fibers in individuals with and without MS.
3.In order to test whether cross-bridge mechanisms of contractionare affected
more in fibers expressing slow versus fast contractile proteins, the MHC
isoform content will be determined in all fibers studied in Aims I and 2. Fibers
willthen be grouped by their isoform composition for statistical analysis.
4.In order to determine whether there is a shift in fiber MHC isoform content in
vastus lateralis muscle fibers from subjects with MS. the MHC isoform content
will be verified on single fibers isolated from muscle biopsies.21
CHAPTER 2
Cellular Mechanisms of Muscle Weakness and Fatigability inIndividuals with
Multiple Sclerosis
Dena J.P. Gamer and Jeffrey J. Widrick
Department of Exercise and Sport ScienceAbstract
Muscle weakness and fatigue are debilitating symptoms of multiple
sclerosis (MS). Approximately 50% of muscle weakness and fatigue have been
attributed to deficits within the peripheral nervous system, specifically mechanisms
residing in the muscle. The goals of this study were to identif' the cellular
mechanisms of contraction within the muscle cell that could contribute to the
muscle weakness arid fatigue in persons with MS. Whole muscle assessment of
knee extensor strength revealed that subjects with MS (N =6) were 48% weaker
than subjects without MS (N = 6). Pedometer results revealed that subjects with
MS were 68% less active on a daily basis than controls. Using an in vitro single
fiber preparation, cross-bridge mechanisms of contraction were tested to understand
their role in muscle weakness and fatigue. Vastus lateralis muscle sampleswere
obtained from subjects with and without MS and 530 single skinned muscle fibers
were mounted between a force transducer and a servo-controlled motor. Number
of fibers were as follows: type I: 134 non-MS, 147 MS; type 1/ha: 3 non-MS, 6
MS; type ha: 114 non-MS, 67 MS; type IIaJIIx: 22 non-MS, 21 MS; type lix: 5
non-MS, 11 MS. Peak Ca2-activated force was 13-44% lower (p<0.05) in type I,
I/ha, IIa/IIx, lix fibers from subjects with MS. The force deficit was attributed to
the 14-32% smaller (p<O.05) cross-sectional area (CSA) of type I, I/ha, ha, lix
fibers and to a 6% lower specific force (p<0.05) in type I fibers from subjects with
MS. While no differences were found between groups for fiber unloaded
shortening velocity, peak absolute power in type I fibers was 11% lower (p<O.O5)23
in subjects with MS. Skinned fiber preparationswere also used to test peakCa2-
activated force at varying concentrations (0-30 mM) of inorganic phosphate(P1)
and at different pH (6.2-7.0). Force declined with increases inP1concentrations,
with a greater reduction of force in type I fibers (66%) versus type ha fibers(40%)
at 30 mM (j<O.05). In contrast, reductions in force at pH 6.5 (17%) and 6.2 (24%)
were similar for type I and ha fibers. These results indicated no difference in fiber
susceptibility to metabolitesP1and hydrogen ions on single muscle fibers from
subjects with or without MS. Assessment of the myosin heavy chains (MHC)
revealed that subjects with MS had 33% fewer type ha fiber than controls, and
there was a trend towards an increased number of type hIaJhIx and lix fibers in
subjects with MS. The results of this study revealed that a portion of the muscle
weakness in individuals with MS is due to deficits at the level of the muscle cell
and cross-bridge.24
Introduction
In the United States there are between 200,000350,000 people with
multiple sclerosis (MS). The risk of a person developing MS is 1 in 1000, with
most developing the disease in their late twenties and early thirties (Joy et al.
2001). The direct and indirect economic costs of MS in the United Statesrange
from 6.5 to 11.9 billion dollars a year, averaging 34,000 dollars perperson
annually. Estimates of the indirect and direct costs associated with MS rank this
disease as the second most costly neurological disease behind Alzheimer's Disease
(Whetten-Goldstein et al. 1998; National MS Society, November 1998).
Although the exact causes of MS are unknown, it is generally considered to
be an autoimmune disease in which the myelin sheath is destroyed resulting in the
slowing or halting of action potential propagation. A slowing or halting of action
potentials leads to the primary and secondary symptoms associated with MS.
Primary symptoms of MS are directly related to demyelination and include
weakness, fatigue, walking difficulties, pain, numbness, and spasticity. Secondary
symptoms occur due to complications and recurrences of the primary symptoms
and include urinary tract infections from repeated bladder dysfunction, and physical
inactivity due to increased fatigue and weakness (McAlpine et al. 1972; Halipike
1983; Joy et al. 2001). Of these symptoms, fatigue and weakness have been cited
as two of the most debilitating and prevalent symptoms, affecting 75-85% of
persons with MS (Freal et al. 1984; Krupp et al. 1988; Matthews 1998).25
Since MS is considered to be a disease principally of the centralnervous
system, researchers initially assumed that the occurrence of muscular fatigue and
weakness in MS was due to problems within the centralnervous system. Deficits
in the central nervous system such as decreased motor unit firing rates, decreased
motor unit recruitment, and increased central motor conduction time have been
shown to contribute to muscular fatigue and weakness in persons with MS (van der
Kamp et al. 1991; Rice et al. 1992; Sharma et al. 1995; Djaldetti et al. 1996;
Sheean et al. 1997; Petajan et al. 2000). Yet not all of the muscular fatigue and
weakness have been explained by deficits within the central nervous system.
Rice and colleagues (Rice et al. 1992) studied the extent of muscle
weakness in MS by examining maximal voluntary and electrically stimulated
contractions. They concluded that approximately 50% of the muscular weakness
could be attributed to peripheral mechanisms of fatigue. Subsequent studies by
Kent-Braun et al. (Kent-Braun et al. 1994) and Sharma et al. (Sharma et al. 1995)
found that approximately 65% of muscle weakness in MS is due to deficits within
the peripheral nervous system, specifically within the muscle cell.
Not only are subjects with MS weaker but they also fatigue significantly
sooner and to a greater extent during an exercise protocol, with prolonged recovery
times versus controls (Kent-Braun et al. 1994; Sharma et al. 1995). Sharma et al.
(Sharma et al. 1995) found that the tetanic force during exercise of the anterior
tibialis from subjects with MS was 25% of controls, while Kent-Braun et al. (Kent-
Braun et al. 1997) found controls exercised 50% longer than subjects with MS26
before fatigue developed in the ankle dorsiflexor. Fifteen minutes post exercise,
Sharma et al. saw that force recovery in subjects with MS was 23% less complete
than subjects with MS (Sharma et al. 1995).
If definitive differences in muscular contractility and compositioncan be
identified as partial causes of muscular fatigue and weakness, then this may enable
researchers to design effective treatments to target these debilitating secondary
symptoms of MS. The purpose of this study was to test the hypothesis that the
muscle fatigue and weakness in MS has a peripheral, cellular component. To test
this hypothesis, an in vitro single fiber preparation was used to investigate, a) cross-
bridge mechanisms of contraction, including peak Ca2-activated force (P0),
maximal shortening velocity (V0), and peak power, b) the effect of metabolites,
specifically inorganic phosphate(P1)and hydrogen ions, on peak Ca2activated
force, and c) the myosin heavy chain (MHC) composition of single muscle fibers
from subjects with and without MS.
Methods
Subject selection
Subjects were recruited from advertisements in the local newspapers and
announcements at local MS chapter meetings. Twelve subjects, six subjects with
MS and six subjects without MS participated in this study. The Oregon State27
University Institutional Review Board approved this project, and all subjectssigned
an informed consent after they were given a full explanation of the study.
Disability status and physical activity
A physical therapist, with experience evaluating functional measures, used
the Expanded Disability Status Scale (EDSS), the modified Ashworth Spasticity
Scale, and the Physiotherapy Clinical Outcome Variables (C.O.V.S.) toassess the
level of disability of the subjects with MS (Kurtzke 1983; Seaby et al. 1989;
Pa.ndyanetal. 1999).
To assess daily physical activity levels, MS and non-MS subjectswore an
activity pedometer (Optimal Health Products Clicker) continually throughout the
day with the exception of sleeping hours. Subjects were trained in properuse of
the pedometers. Stride length for each subject was measured and subsequently
recorded in the pedometer. Pedometers were worn for a period of 14 consecutive
days, and at the end of each day subjects recorded total miles and steps taken for
that day.
Muscle biopsy
Muscle biopsies from the vastus lateralis were obtained using the
percutaneous biopsy technique (Bergstrom 1975). Based on the functional
assessment of the physical therapist, the subject's weakest leg was biopsied. The
muscle biopsy was immediately placed in dissection solution where itwas28
dissected into 8-10 separate bundles. A large bundle was frozen and stored in
liquid nitrogen for MHC isoform analysis. The other bundleswere stored in
skinning solution (for composition, see Solutions section). This solution
chemically skins the fibers, permeabilizing the t-tubules, sarcoplasmic reticulum,
mitochondria, and the sarcolemma, while leaving the cross-bridges and thin
filament regulatory proteins intact. Bundles were stored at 4°C for 24 hours and
then transferred to fresh skinning solution and stored for up to 30 days at -20°C.
Evaluation of neuromuscular strength
Subjects returned to the laboratory approximately two weeks after the
muscle biopsy procedure. Muscle strength in the quadriceps was assessed using an
isokinetic dynamometer (Chattecx Corporation, KinCom III; Hixson, 1'N). The
lateral condyle of the knee was aligned with the axis of the dynamometer lever arm
with the knee and hip at 90° of flexion. The subject's thigh was then strapped to
the seat with a Velcro strap, a seat belt was fit across the lap, and another Velcro
strap was fit across the chest to limit extraneous movement and the use of muscles
other than the quadriceps. The force transducer was attached to the lever arm and
to the lever arm the subject's medial malleolus was secured with a Velcro strap.
Measurements were conducted on the biopsied leg. Each protocol was
preceded by two warm-up trials. The first test protocol was an isometric test in
which the subjects used the knee extensors and performed three consecutive
maximal voluntary isometric contractions. Each contraction lasted for 5 secondsrs
with approximately one minute separating each trial. The second protocolwas
isokinetic knee extension in which the subject's maximal voluntary concentric knee
extension strength was tested at angular velocities of 30°, 60°, 120°, 180°, and 240°
per second, through a range of 10°-90° of knee flexion. Subjects completed three
trials at each angular velocity with approximately one-minute rest after each test.
The highest value during the three trials of each test was used for statistical
analysis.
Solutions
One relaxing solution and nine different activating solutions were used in
this study. All solutions contained: 7.0 mM EGTA, 20.0 mM imidazole, 1 mM free
Mg2, 4 mM Mg2-ATP, 14.5 mM creatine phosphate, and 15 Umi' creatine
kinase. A CaCl2 standard solution was used to adjust the freeCa2concentration of
the relaxing solution to pCa 9.0 (pCa = -log[Ca2]) and all of the activating
solutions to pCa 4.5. The pH of the standard activating solution and relaxing
solution was 7.0 (adjusted with KOH) and neither solution containedany added P1.
A second activating solution contained 30 mM P1(adjusted with KH2PO4), pH 7.0.
Five additional activating solutions of varying concentrations of P1(2 mM, 5 mM,
10mM, 15 mM, and 20 mM), all pH 7.0, were obtained by mixing aliquots of the 0
mM P1activating solution and the 30 mMP1activating solution. The final two
activating solutions contained no added P1but had a pH of 6.5 and 6.2, respectively.
The total final ionic strength was 180 mM (adjusted with KC1) for all solutions.The composition of all solutions used in these experiments was determined using
the iterative computer program of Fabiato (Fabiato 1988) and apparent stability
constants adjusted for total ionic strength, temperature (15°C), and pH (Fabiato
1985).
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The dissection solution consisted of protease inhibitors dissolved in relaxing
solution (Complete Mini EDTA-Free Protease Inhibitor Tablets, Boebringer
Mannheim, Indianapolis, IN). The skinning solution consisted of 50% dissection
solution and 50% glycerol.
Experimental instruments
The experimental apparatus used in the single fiber experiments included a
force transducer (Aurora Scientific, Aurora Ontario; Model 400), a high-speed
servomotor (Aurora Scientific; Model 308B), a stainless steel plate with three
chambers, two stainless steel troughs for fiber attachment, an aluminum-cooling
block, and a thermocouple. The foundation of the experimental apparatus wasa
stainless steel, spring-loaded dip-plate into which three stainless steel chambers
were milled, with each chamber holding -250ml of solution. Located on either
side of the stainless steel plate were the servomotor and force transducer. Two
stainless steel troughs, extending from the servomotor and force transducer, were
suspended within a chamber and held the single muscle fiber during the
physiological experiments. Peltier cells and an aluminum cooling block worked in
conjunction with a circulating water bath to heat or cool the experimental apparatus31
so that solution temperature was maintained at 15°C + 0.5°C throughout the
experiment.
Mounting of fibers and measurement of fiber CSA and length
Muscle fiber segments (-5 mm in length) were isolated from the muscle
bundle in a chamber containing relaxing solution. The ends of the segment (-1nmi
of each end) were attached to the stainless steel troughs. To attach the fiber,a 4.0
monofilament post placed on top of each fiber end and 10.0 suture were used to tie
the post securely into the trough. Once the fibers were secured to the troughs, the
experimental apparatus was mounted to the stage of the inverted microscope
(Olympus IX-70). The fiber was observed (600x) through a glass plate that formed
the bottom of each chamber.
Sarcomere length was adjusted to 2.5 im using a calibrated eyepiece
micrometer. Fiber length was measured using a digital micrometer. Fiber width
was read from the eyepiece micrometer at three points along the length of the fiber,
at approximately 25%, 50%, and 75% of fiber length. Width measurements were
conducted while the fiber was briefly suspended in air (<5 s). The fiber was
quickly returned to the relaxing solution between each of the three measurements.
Fiber cross-sectional area (CSA) was calculated from each width measurement with
the assumption that the fiber forms a cylinder while in air (Metzger et al. 1987;
Widrick et al. 1996). Final fiber CSA was the mean of these three CSA
measurements.32
Output from the force transducer and position motorwas monitored on a
digital oscilloscope (Integra 10, Nicolet Technologies, Madison, WI). Amplified
signals (Model 300-FC1, Positron Development, Inglewood, CA)were digitized
(5Hz) and interfaced to a personal computer by a data acquisition board (Model
AT-MIO-16E, National Instruments, Austin, TX). Custom software (Lab View,
National Instruments) was used to control the experiments and to store and analyze
data.
Physiological experiments
The maximal Ca2-activated force (P0) and the unloaded shortening velocity
(V0) of the fiber were measured by the slack test procedure. During the slack test
procedure, the fiber was placed in an activating solution containing 0 mM of added
P1and pH 7.0. The fiber was subjected to a series of 5 steps, with each slack step
greater in length and no step exceeding 20% of the fiber length (Edman 1979)
(Figure Ia). The time it took for tension to re-develop after each slack stepwas
plotted versus the slack step length, and the slope of the line fit to these pointswas
V0(Figures lb). Since the shortening velocity is proportional to the fiber length,V0
was divided by fiber length and expressed in normalized terms, i.e. as fiber lengths
per seconds (FlIs). TheP0was determined from the difference in the baseline
measurement of force in the relaxing solution and the peak force obtained when
placed in activating solution.33
Fibers were subjected to a series of isotonic contractions in orderto obtain a
force-velocity and a force-power relationship. The fiberwas activated in the
standard activating solution (0 mMP1,pH 7.0). After the fiber reached peak force,
it was subjected to three isotonic load steps. The duration of eachstep varied
between 60-100 ms for fast fibers and 100-150 ms for slow fibers. The shortening
velocity (slope of the position signal) and force of each isotonic stepwas assessed
over the final one-fourth of the isotonic step. Data were fit to the Hill equation
(Hill 1938) (Figure 2). The following parameters which describe the Hill equation
were determined: Vmax, the velocity extrapolated to a force of zero; P0, force
attained at a velocity of zero; and aIP(), a unitless parameter describing the shapeor
curvature of the force-velocity relationship (Woledge et al. 1985). Peak power was
calculated from these three parameters (Woledge et al. 1985). Powerwas
expressed in absolute terms, the product of force (mN) and the shortening velocity
(FLIs), and in normalized terms, the product of the specific force (kN/m2) and
shortening velocity (FL/s), which is equivalent to Watts/Liter of fiber (Widrick et
al. 1995; Widrick et al. 1996).
Peak Ca2-activated force was measure at variousP1and H concentrations
in a sub-group of fibers. Fibers were placed in activating solutions containing
varying pH (7.0, 6.5, and 6.2), or varying concentrations ofP1(0 mM, 2 mM, 5
mM, 10 mM, 15mM, 20 mM, and 30 mM) (Figures 3 and 4). Peak force in each
solution was measured as the difference between the force in relaxing solution and34
peak force attained during the contraction. Activating solutions were stirred to
prevent the formation ofP1of H gradients within the fiber (Kentish 1991).1UO ms
Figure la. Superimposed force records following slack steps at 200, 250,
300, 350, and 396. Time required for force redevelopment was determined
from each record and plotted in Figure lb. Calibration bars are 0.05 mN
and lOOms.
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Figure lb. Time for force development vs. slack distance was fit with a
linear regression. The slope of the relationship is the fiber's maximal
shortening velocity (V0).V0was normalized to fiber length (FL).
Experiment #2889: slope1.89,r2= 0.998, FL3.06 mm,V00.62 FL/sCl)
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Figure 2. Force-velocity relationship for a single human muscle fiber. Inset:
position and force records obtained during 3 isotonic contractions at peak
Ca12-activated force (P0). Isotonic force for the 3 stepswas 42, 32, and 12%
of P0, and corresponding shortening velocities were 0.201, 0.154, and 0.059
FL/s. These data points were plotted and indicated by corresponding points,
A, B, and C. This was repeated 3 times resulting in 9 points (as seen on
graph), which were fit by the Hill equation.Pu5 P120 P130 P10
Figure 3. Effect of different concentrations ofP1on peak Ca2-activated force on a single skinned muscle fiber
expressing type ha MIHC. Each trace represents a fiber that rapidly attained peak force after being placed in
activating solution after which it was returned to the relaxing solution. Sharp spikes in a trace represent
movement artifact.
LiLL
Figure 4. Effect of different pH on peak Ca2-activated force on a single skinned muscle fiber expressing
type ha MT-IC. Each trace represents a fiber that rapidly attained peak force after being placed in activating
solution after which it was returned to the relaxing solution. Sharp spikes in a trace represent movement
artifact.
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Gel electrophoresis
After the physiological analysis of the single fiber was completed, the fiber
was removed from the stainless steel troughs and stored in 30.tlof SDS sample
buffer (containing 62.5 mM Tris (iH 6.8), 2% SDS, 10% glycerol, 5% beta-
mercaptoethanol, and 0.00 1% bromophenol blue). Each fiber was denatured for 4
minutes at 95°C and stored at 80°C. Later, a portion of the denatured solute was
electrophoresed on polyacrylamide gels to determine the fiber MHC isoform
composition. MHC isoform separation was performed on 7% separating gels with
a 3.5% stacking gel. A Bio-Rad mini-Protean 3 electrophoresis system (Bio-Rad
Laboratories, Hercules, CA) was used to run the gels at a voltage of 70 for a period
of 22 hours (Fauteck et al. 1995). A silver staining procedure was used to visualize
the protein bands (Shevchenko et al. 1996). Fiber MHC isoform content was
evaluated by comparison to human myosin standards run on one or more lanes of
each gel (Figure 5).39
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Figure 5. Silver stained 7% polyacrylamide gel electrophoresis of human
fibers expressing type I, ha, and lix MHC as compared to a human vastus
lateralis muscle standard. Lane 1: type I; lane 2: type ha; lane 3: MHC
standard expressing type I, ha, and lix; lane 4: type ha; and lane 5: type lix.
Each lane contains a single muscle fiber.40
Statistics
One-way ANOVA was used to compare the physiological properties(P0,
V0, Vmax, a/P0, and peak power) of fibers from non-MS and MS subjects.
Separate analyses were conducted on MHC type I, I/ha, ha, Ila/lix, and lix fibers.
A repeated measures ANOVA compared the relative force at eachP1and H
concentration for slow and fast fibers obtained from MS and non-MS subjects.
Significance was set at p<O.O5 for all statistical tests.
Results
Disability status
The mean age (49 ± 2), height (177±4 cm), and weight (77±7 kg) of
subjects with MS were not statistically different from the mean age (45 ± 3), height
(175 ± 6 cm), and weight (83 ± 7 kg) of the subjects without MS. All MS subjects
were ambulatory, with 2 subjects using canes. The mean EDSS rating of the
subjects with MS was 4.75 ± 0.28, their mean C.O.V.S. rating was 8 1/90, and their
modified Ashworth Spasticity Scale ratings ranged from 0 to +1.
Physical activity levels
The pedometer results showed that subjects with MS walked significantly
fewer steps (MS: 2657 ± 517 steps, n = 4; non-MS: 8317.22 ± 1153 steps, n = 4;41
p<O.O5) and significantly fewer miles (MS: 0.96 ± 0.21 miles,n = 4; non-MS: 3.84
± 0.34 miles, n =4; p<O.O5) during a day than subjects without MS.
Neuromuscular strength
All neuromuscular measurements were expressed relative to bodymass to
normalize for differences in body sizes. There were significant differences in peak
isometric torque (Nm/kg), isokinetic force (Nm/kg), and power (Watts/kg) between
subjects with and without MS. At all angular velocities tested, subjects with MS
had a 44% deficit in peak isometric force as compared to the subjects without MS
(Figure 6). Isokinetic force averaged 41% less in the subjects with MS (Figure 6),
while peak power at 240°/second was 48% lower in subjects with MS versus
subjects without MS (Figure 7).42
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Figure 6. Isometric force and torque at angular velocities of 30, 60,
120, 180, 240. Subjects with MS (triangles) and without MS
(circles). Isometric peak force is indicated at 0 degrees/second. All
values are mean ± SE, and measurements are expressed relative to
body mass (Nmlkg: Newton meters/kilogram).I-
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Figure 7. Peak power at angular velocities of 30, 60, 120, 180,
240. Subjects with MS (triangles) and without MS (circles).
All values are mean ± SE, and measurements are made
relative to body mass (Nm/kg: Newton meters/kilogram).
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Fiber CSA
The CSA of all fibers expressing type I, I/ha, ha, and lix MHC isoforms
from subjects with MS were 8-32% smaller than the CSA of similar fibers obtained
from subjects without MS (Table 1). Type I and ha fibers from subjects with MS
were 8% and 14% smaller, respectively, than the same fiber types from subjects
without MS. Type I/ha, IIaJIIx, and lix fibers from subjects with MS showed the
greatest deficit in CSA at 31%, 29%, and 32%, respectively, as compared to these
same fiber types in subjects without MS. Although there was no significant
difference found in the IIa/hhx fiber types between groups, CSA approached
statistical significance with a p-value of 0.0598.
Fiber force
The absolute force (mN) of fiber types I, h/Ila, hia/hix, and lix was
significantly lower in fibers from subjects with MS as compared to non-MS fibers.
The absolute force across all fiber types in subjects with MS was on average 25%
lower compared to fibers from subjects without MS. MS type JJIIa showed a 45%
reduction in absolute force, while type I, ha, hIa/Ihx, and IIx showed reductions
ranging from 13-30% versus those same fiber types from subjects without MS
(Table 1).
Specific force (kN/m2) was greater in fast fiber types (ha, hIa/hhx, andlix)
versus slow fiber types (I and I/ha) regardless if the fiber was from subjects with or
without MS. The specific force (kN/m2) was significantly lower, 6%, in the type I45
fibers from subjects with MS. Though there were no significant differences found
in other fiber types, type I/ha from subjects with MS showeda 21% deficit in
specific force versus controls (Table 1).
Unloaded shortening velocity and force-velocity-power relationships
Unloaded shortening velocity was slowest in type I fibers, with incremental
increases inV0in type I/ha, ha, hIaJIIx, and lix (Table 2).There were no
differences in unloaded shortening velocity between fibers from subjects with and
without MS. Similar to unloaded shortening velocity from slack tests results, there
were no differences in maximal shortening velocity (Vmax) between subjects with
and without MS (Table 3). However unlike slack tests, extrapolation of the force.-
velocity relationship failed to differentiate between fibers expressing fast isoforms
(Table 3).
Absolute power is the total power that a fiber can produce, whereas,
normalized power accounts for CSA of fiber. Power data revealed that absolute
and normalized power was greatest in fibers expressing type lix MHC (lix or
hla/Ux), with ha MHC expressing intermediate power and type I MHC having the
lowest power of all fiber types. Type I fibers from subjects with MS had
significantly less, 11%, absolute power than subjects without MS, yet there were no
differences in absolute power in type ha, hIaJIIx, or lix. There were also no
significant differences in normalized power between groups (Table 3 and Figure 8).46
Table 1. Cross-sectional area, absolute and specific force values for fibers
expressing type I, I/ha, ha, hIaIIIx, and lix MHC
Number
MHC Treatmentof fibersCSA (.tm2) Po (mN) Po/CSA(kN/m2)
Type I Non-MS 134 6153 ± 165 0.68 ± 0.02 112 ± 1
MS 147 5672±175* 0.59±0.02* 105±2*
Type I/HaNon-MS 3 6980±745 0.83±0.05
MS 6 4826±515* 0.46±0.10*
Type haNon-MS 114 5906 ±217 0.81±0.03
MS 67 5084±333* 0.71±0.04+
121±6
95 ± 14
139 ±2
143±2
Type Ila/lix Non-MS 22 5686±664 0.79±0.08 147±5
MS 21 4066±499+ 0.58±0.07* 143±5
Type lix Non-MS 5 6333±846 0.90±0.12 143±6
MS 11 4332±502* 0.63±0.07* 153±9
Values are mean ± SE. Abbreviations: MHC, myosin heavy chain isoform; CSA, cross-sectional
area;P0.peak Ca+2activated force; .tm2, micrometers squared; mN, milli-newtons; kN/m2, kilo-
newtons per square meter of fiber. * indicates a significant difference (p<O.OS) between MS and
non-MS fibers and + indicates (0.O5<p<O. 10).47
Table 2. Unloaded shortening velocity of fibers expressing type I, I/ha, ha, hla/hix,
and lix MIIC
Number
MHC Treatment of fibers Vo (FL/s)
Type I Non-MS 105 0.61±0.01
MS 130 0.61±0.01
Type 1/ha Non-MS 3 1.57± 0.30
MS 2 1.81±0.11
Type Ha Non-MS 90 2.55±0.09
MS 54 2.80±0.13
Type flaIHx Non-MS 18 4.19±0.29
MS 14 4.54±0.37
Type lix Non-MS 5 5.27±0.43
MS 9 5.07±0.46
Unloaded shortening velocity determined by slack test. Values are mean ± SE. Abbreviations:
MEC, myosin heavy chain isoform; CSA, cross-sectional area; FL/s, fiber lengths per second.48
Table 3. Maximal shortening velocity, absolute power and normalizedpower for
fibers expressing type I, ha, IIaJIIx, and lix MHC
Number of Absolute Normalized
MHC Treatmentof fibersVmax (FL/s) power power
Typel Non-MS99 0.78±0.03 9.67±0.36 1.57±0.03
MS 113 0.79±0.03 8.59±0.35* 1.51 ±0.04
Type haNon-MS 86 1.87 ±0.06 47.70± 1.88 8.50 ±0.18
MS 43 1.89 ± 0.07 44.91 ±3.30 8.92 ± 0.37
Type hIa/llxNon-MS 17 2.22 ±0.16 52.91 ± 4.16 12.39± 1.27
MS 14 2.83 ± 0.39 47.77 ± 7.23 12.57 ± 1.27
Type lix Non-MS 5 1.50 ± 0.19 68.90 ± 7.32 11.40 ± 1.59
MS 7 1.63 ± 0.35 51.20 ± 12.3913.20 ± 2.81
Values determined by force-velocity relationship. Values are mean ± SE. Abbreviations: MHC,
myosin heavy chain isoform; Vmax, maximal shortening velocity; FL/s, fiber lengths per second.
* indicates a significant difference (p<O.O5) between MS and non-MS fibers.49
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Figure 8. Force-velocity and force-power curves for type I fibers from
subjects with and without MS. Dotted lines indicate subjects with MS
and solid lines are subjects without MS. Darker lines indicate force-
power relationships and lighter lines are force-velocity relationships.50
Effect ofP1on peak force
Peak Ca2-activated force declined rapidly asP1concentration increased
from 0 to 10 mM P1. Smaller decreases in peak Ca2-activated force occurredas P,
increased from 10 mM to 30 mM. This relationship held for both fiber types (I and
ha), although the magnitude of change was greater in the type I fibers, resulting in
a significant difference between fiber types with varying concentrations of P1. At
30 mM of P1, type I fibers on average produced 66% less force than at 0 mM ofP1
while type ha fibers produced 40% less force at 30 mM ofP1as compared to initial
force at 0 mM ofP1.No significant differences between groups within the same
fiber type were found with various concentrations ofP1(Figure 9). These effects of
P1were not due to run-down of the fibers because force at 0P1following the 30
mM ofP1 trial was 101 % and 99% of the original 0mMP1force for type land type
ha, respectively.51
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Figure 9. Effects ofP1on peak Ca2-activated force in type I and
Ha skinned single fibers from subjects with and without MS.
Circles indicate subjects with MS and squares indicate subjects
without MS. Each point represents mean values from each fiber
type. Number of fibers studied used to obtain mean values
included: type I: non-MS, N = 33; MS, N = 34, type Ha: non-
MS, N = 25, MS, N = 24. Significant main effects were found
between fiber types (p<O.O5), but there were no significant
differences between groups.52
Effect of pH on peak force
Peak Ca2activated force in both type I and ha fibers decreased with
increasing concentrations of pH. At pH 6.5, there was an average force reduction
of 17% in both fiber types, while at pH 6.2 there was an average force reduction of
24% in both fiber types. There were no significant differences between groups at
different pH, nor were there differences between fiber types (I and ha) at different
pH. The effects of pH were not due to fiber run-down because force at the last pH
7.0 in type I fibers was 100% of the initial force value at pH 7.0, and the force of
type ha fibers was 98% of the initial force value at pH 7.0 (Table 4).
Table 4. Effects of different pH on peak Ca2-activated force in fibers expressing
type I and ha MHC
MHCTreatmentNo. fiberspH 7.0 pH 6.5 pH 6.2 pH 7.0
Type!Non-MS
MS
20
20
103 ±4
103±4
85±3
87±3
78±2
80±3
102 ±4
104±4
Type ha Non-MS 24 148 ±3 123 ±3 112 ±2 146 ±3
MS 21 155±5 128±4 116±4 153±5
Values are mean ± SE. Abbreviations: MHC, myosin heavy chain; No. fibers, number of fibers.
All force measurements were made in kilo-newtons per squared meter of fiber (kN/m2) and values
are mean ± SE.53
Myosin heavy chain isoforms
There was wide variation in the relative MHC isoform expression in
muscle fibers of MS and non-MS subjects. For example MS-i had 63% type I
fibers, 33% type ha fibers, 3% type lia/lix fibers, and 1% type lix while MS-6 had
28% type I fibers, 28% type ha fibers, 27% type Ila/lix fibers and 10% type lix
fibers (Figure 10). Average percentages for MHC expression in type I, hIIIa, ha,
hIaJIIx, and lix fibers of controls were 40, 3, 46, 10 and 2%, respectively, while
average percentages for these same fiber types in subjects with MS were 46, 3, 31,
13, and 8%, respectively. A significant difference was found in the relative number
expressing type ha fibers between groups, with subjects with MS expressing 33%
fewer type ha fibers than subjects without MS. While there were no significant
differences between groups in comparing the expression of faster fiber types
(lia/lix and lix), the data showed that there was a trend towards increased
percentage of these fiber types in MS versus controls. The data also revealed that
there was a trend towards a decreased percentage of type I fibers as the EDSS score
rose in subjects with MS.54
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Figure 10. Percentage of myosin heavy chain (MHC) isoform expression
from single fibers in subjects with and without MS. The number of fibers
analyzed from each subject with or without MS ranged from 87-140. Each
bar represents the MHC composition for one subject. Individual MS subjects
are indicated by MS-i, MS-2, etc. while individual subjects without MS
(controls) are indicated by Con-i, Con-2, etc. EDSS scores for each subject
are listed below bars.55
Discussion
All of the subjects with MS in this study were ambulatory, with two of the
subjects using walking aids for assistance. On average, subjects with MS had been
diagnosed for 13.5 years. The level of disability as described by the EDSSscores,
ranged from 4.0 to 6.0. A score of 4.0 indicates that subjects were able to walk 500
meters without a walking aid, while subjects with a score of 6.0 walked a
maximum of 200 meters (Kurtzke 1983). The C.O.V.S. score was a measure of
quality of gait and movement, and these scores ranged from 75/91 to 89/91, with
the lowest C.O.V.S. score indicating greater deficits in movement and gait quality
(Seaby et al. 1989). The modified Ashworth Spasticity Scores were +1 or less
which indicates that subjects had minimal or no spasticity (Pandyan et al. 1999).
The present MS subjects are similar in disability status to MS populations used in
previous studies which assessed muscle weakness and fatigability (Kent-Braun et
al. 1994; Sharma et al. 1995; Lambert et al. 2001).
The results of this study show that subjects with MS are significantly
weaker at the whole muscle level than subjects without MS. Peak power and
isokinetic torque of the knee extensors were 48% and 41% lower, respectively,
while peak isometric torque was 44% lower in subjects with MS as compared to
controls. This compares favorably to previous studies which found that subjects
with MS were 26-39% weaker in lower limb muscle strength as compared to
controls (Kent-Braun et al. 1994; Sharma et al. 1995; Schwid et al. 1999; Lambert
et al. 2001). This study tested the novel hypothesis that these changes in muscle56
strength in persons with MS are due to deficits in cellular mechanisms of
contraction. Specifically, this study tested the hypotheses that muscle weakness in
MS may be due to changes in CSA of muscle fibers or deficits at the level of the
cross-bridge as indicated by changes in Ca2-activated P0. V0, and peak power.
The CSA of fibers from subjects with MS was significantly smaller than
CSA of fibers from subjects without MS. Type I and ha fibers were 8% and 14%
smaller, respectively, while type I/ha, Ila/lix, and lix were 29-32% smaller than
those from the subjects without MS. These findings are similar to those reported
by Kent-Braun et al. who found 25-36% atrophy of type I, ha and IIaJx fibers in
subjects with MS (Kent-Braun et al. 1997). These authors also saw a greater
atrophy in the faster fiber types, which follows the trend in the present study.
This study also found significant reductions in absolute and specific force
and absolute power in subjects with MS. There was a 23% decrease in absolute
force in all fiber types from subjects with MS. Absolute force in the type I fibers
was 13% lower and the specific force was 6% lower than the absolute and specific
force of type I fibers in controls. Absolute power in the type I fibers from subjects
with MS was 11% lower than the absolute power of type I fibers from controls.
While the significant reductions in absolute force and absolute power could be
attributed to atrophy of the muscle fibers, the significant difference in specific force
of the type I fibers is attributed to deficits at the level of the cross-bridge. Deficits
in cross-bridge cycling may include shifts from high force producing states to low57
force producing states or loss of cross-bridges due to atrophy of thick and thin
filaments.
This study found that subjects with MS are significantly weaker at the
whole muscle level than subjects without MS. Results from in vitro preparation
indicate that muscle fiber atrophy and cross-bridge mechanisms can account for
approximately half of the observed peripheral weakness. Since deficits at the level
of cross-bridge cannot account for all of the whole muscle weakness seen in the
MS subjects, the remainder of whole muscle deficit must be due to other cellular
mechanisms of contraction. One possibility is that there are impairments in
excitation-contraction coupling. Sharma et al. (Sharma et al. 1995) and Kent-
Braun et al. (Kent-Braun et al. 1994; Sharma et al. 1995) suggested that in MS the
lower tetanic force and increased time to recover after exercise may be a result of
decreased amounts of calcium being released from the sarcoplasmic reticulum
and/or by abnormalities in the calcium pump, both mechanisms involved in
excitation-contraction coupling.
While muscle weakness was evident in the present study and in previous
studies that investigated whole muscle strength in subjects with MS, the
explanations for this increased muscle weakness are not clear. One possible
explanation for increased muscle weakness in these subjects with MS may be due
to the lower physical activity levels observed in these subjects with MS. Models
of disuse, spaceflight, bed-rest and spinal cord injury, have cited changes in muscle
CSA and absolute and specific force after disuse. Changes in CSA after spaceflight58
and bed-rest have shown a 15% and 5% decrease in CSA of type I fibers,
respectively. Type II fibers have shown a 26% and 24% reduction in CSA after
spaceflight, while spinal cord injury reports a 40% reduction in CSA of thetype
Ilax fibers (Edgerton et al. 1995; Castro et al. 1999; Widrick et al. 1999). Asa
result of muscle atrophy, absolute force of type I fibers is reduced 21% and 13%
after spaceflight and bed-rest, correspondingly (Widrick et al. 1997; Widrick et al.
1999). When cross-sectional area was taken into account, Widrick et al. reported a
6% loss of specific force in type I fibers after 17-days of spaceflight (Widrick et al.
1999), suggesting impairments in cross-bridge mechanisms of contraction.
Results from this study reveal that the changes in MS are comparable to
changes occurring from short-term disuse. Thus, increases in physical activity may
alleviate some of the muscle weakness in individuals with MS. Strength training
studies have been shown to increase muscle CSA with a corresponding increase in
absolute force in young male subjects without MS, with no effects seen inV0
(Widrick et al. in press). Endurance training studies have shown no effects on CSA
and force in muscle fibers in elite older athletes (Widrick et al. 1996). Therefore,
strength training exercise interventions rather then endurance training may result in
increased CSA and absolute force in persons with MS.
In studying the mechanisms of fatigue in subjects with MS, there were no
significant differences with varying concentrations of P, or changes in pH.
However, there were significant differences between fiber types with varying
concentrations ofP1.This finding is significant in that it is not known if there areany other studies that have assessed the effect ofP1on human single muscle fibers.
AtP1of 30 mM, the force of slow fibers was 66% lower than at the 0 mMP1
condition, while in fast fibers there was a 40% deficit at 30 mM ofP1from 0 mM P,
condition. Using solutions and methodology identical to this present study,
Widrick (Widrick 2002) found that the force of type I rat fibers was depressed 44%
and the force of the type lib rat fibers was depressed 42% at 30 mlviP1.Thus, it
appears that the peak Ca2-activated force of human type I fibers are more sensitive
than the rat type I fibers to increases inP1concentration.
Although there were no significant differences between groups and fiber
types at different levels of pH, this fmding is important in understanding the effect
of pH in human single muscle fibers. The results of thisstudyshowed an average
17% and 24% deficit in force at pH 6.5 and 6.2, correspondingly. Lynch et al.
(Lynch et al. 1994) assessed the effect of pH in human fibers and found that there
was a 7% and 21% loss of force at pH 6.6 in type I and type ha fibers, respectively.
The type I fiber discrepancies between this present study and Lynch et al. may be
due to differences in fiber typing techniques and in the functional assays utilized by
Lynch and colleagues.
Muscle fatigue in MS may also be attributed to shifts from slower oxidative
fibers to faster glycolytic fibers. The myosin heavy chain data revealed that there
were differences in fiber MHC isoforms between groups. Controls had
significantly greater relative numbers, 33%, of ha fibers than subjects with MS.
While there were no significant differences found in IIaJIIx and lix fiber typesbetween groups, there was a trend towards an increased percentage of these fiber
types in subjects with MS. In addition, there were no differences in the relative
number of type I fibers between groups, yet there was a trend towards a decreased
percentage of type I fibers as the level of disability increased, as indicated by the
EDSS scores. These data also suggest a shift from the type ha to type lix MHC
expression in MS. The larger number of fibers co-expressing hIa/llx MHC in
subjects with MS is consistent with this interpretation, since fiber type shifts are
thought to progress from ha to IIaIIIx to lix. This could explain the increased
fatigability in subjects with MS since type hla/lix and lix fibers are the most
fatigable fiber types, with type lix being the most fatigable of these two.
In comparing these MHC isoform results to a previous study by Kent-Braun
Ct al. (Kent-Braun et al. 1997) there were notable similarities and differences
between the two studies. The results in this study found an increased percentage,
28%, of type hla/hix fibers in subjects with MS as compared to subjects without
MS. This fmding is similar to that of Kent-Braun et al. (Kent-Braun et al. 1997)
who found a 22% increase in type Ila/hix fibers in subjects with MS. In contrast to
the present findings, Kent-Braun et al. (Kent-Braun et al. 1997) found a 13%
decrease in type I fibers and a 32% increase in type ha fibers in subjects with MS.
The differences between this present study and that of Kent-Braun et al. could be
explained by differences in the muscles studied. This study investigated the vastus
lateralis, while Kent-Braun et al. analyzed the anterior tibialis of subjects with MS.
The vastus lateralis of control subjects expressed 40% type I, 45% type ha, and 3%61
type lix fibers versus the tibialis anterior of controls which expressed 76% type I,
28% type ha, and 6% type Ilax fiber types. Thus, a pre-dominantly slow muscle
like the anterior tibialis may respond differently to disuse thana mixed muscle like
the vastus lateralis.
Conclusions
Previous studies have shown that part of muscle weakness in MS is due to
deficits within the central nervous system, while approximately half of the muscle
weakness may be attributed to peripheral deficits (Rice et al. 1992; Kent-Braun et
al. 1994; Sharma et al. 1995). This study found that subjects with MS are
significantly weaker at the whole muscle level than subjects without MS. Results
from an in vitro preparation indicate that muscle fiber atrophy and cross-bridge
mechanisms of contraction can account for approximately half of the observed
peripheral weakness. Fibers from subjects with MS were significantly smaller and
produced significantly less absolute force than controls. In addition, the lower
specific force in type I fibers from subjects with MS suggests deficits with cross-
bridge mechanisms of contraction. There was no evidence at the level of the cross-
bridge to suggest that increased muscle fatigability in MS is due to a greater
sensitivity to changes in the metabolitesP1and H. This study found that
approximately half of the peripheral weakness could be explained by cross-bridge
mechanisms of contraction and muscle atrophy, while muscle fatigue could not be
explained at the level of the cross-bridge. Thus, future studies should examine62
other cellular mechanisms, such as excitation contraction coupling, that would
contribute to the increased peripheral weakness and fatigability inpersons with
MS.63
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A. Title of the Research Project:Cellular mechanisms of muscle contraction in
individuals with multiple sclerosis
B. Principal investigator: Dena Gamer, M.S.
Doctoral student
Dept. of Exercise and Sport Science
541-737-6619
Co-investigators: Jeffrey Widrick, Ph.D.
Assistant Professor
Dept. of Exercise and Sport Science
541-737-5923
Jeffrey McCubbin, Ph.D.
Director, Special Motor Fitness Clinic
Professor and Associate Dean
Dept. of Exercise and Sport Science
541-737-5921
C. Purpose of the Research Project.
The purpose of this project is to study processes within individual muscle cells
(muscle fibers) that could contribute to the muscle weakness and fatigue
associated with Multiple Sclerosis. To gain an understanding of muscle cell
processes, a comparison of muscle strength and muscle fiber composition will
be made between subjects with and without Multiple Sclerosis.
D. Procedures. I have received an oral and a written explanation of this study and I
understand that as a participant in this study the following things will happen:
1.Pre-study screening. I will complete an interview pertaining to my level of
disability and physical activity levels in order to determine whether I am a
suitable candidate for this study. After completion of this pre-screening, I
may or may not be asked to participate in the remainder of the study.73
2. What I will be asked to do during the study. If! am chosen to participate in
this study, I will be asked to do the following:
Day 1:
a) My weight and height will be determined.
b) Disability Status. A physical therapist will evaluate the level of my
disability using the Expanded Disability Status Scale (EDSS).
During this assessment, the level of my functional impairment along
with gait analysiswillbe assessed. The modified Ashworth
Spasticity Scalewillalso used to evaluate spasticity levels, while the
Physiotherapy Clinical Outcomes Variables (C.O.V.S.) assessment
willbe used to determine the level of my physical mobility.
c) Muscle biopsy. A physicianwillobtain a muscle sample from the
thigh muscle (vastus lateralis) of my dominant leg. The method used
to obtain this sample (percutaneous needle biopsy technique) is
routinely used by the medical community to obtain small muscle
samples for the assessment of neuromuscular diseases. Muscle
samples obtained in this way typically weight between 2-4 one-
thousandths of an ounce (0.002-0.004 ounce), about the size of a
match head. A local anestheticwillbe injected at the sample site on
my thigh. I may experience a stinging sensation as the anesthetic is
injected. A small incision (-3/8 inch long)willbe made through the
skin and the sheath that surrounds the muscle. I understand that I
will have a small scar as a result of the incision. To obtain the
muscle sample, a biopsy "needle" (- 2/10 of an inch in diameter) is
inserted through the incision and into the muscle. Most people report
feeling an odd, "pressure," sensation as this is done.
d) Physical activity levels. In order to determine my physical activity
levels, Iwillcomplete the Yale Physical Activity Questionnaire.
This test includes questions pertaining to the activities of my daily
living such as yard and home activities. This questionnaire also
includes questions concerning my level of recreational physical
activity such a walking, swimming, or participation in team sports.
My physical activity levelswillalso be monitored with an Optimal
"Clicker" Pedometer. This pedometer records steps, miles, and
calories burned during a day. Iwillput on the pedometer as soon as
I get up each morning and take it off when I am going to bed for the
evening. At the end of the day, Iwillrecord the number of steps,
miles, and calories that I burned during that day on a data sheet,
whichwillbe supplied for me. Iwillwear the pedometer for a
period of 14 days.74
Day 14:
a) Muscular strength. The strength of my leg muscles will be evaluated
using aKin-Corn isokinetic strength testing apparatus. This test
involves making maximal contractions with each leg againsta
pivoting or stationary lever. Each leg will perfonn24 contractions
or until it is fatigued, whichever comes first.
3.Foreseeable risks or discomforts.
a) Muscular strength testing. I may experience some muscle soreness
2-3 days after this testing. This is a normal response to
unaccustomed exercise andwillsubside within another 1-3 days.
b) Muscle biopsy. Following the biopsy procedure, I may experience
muscle soreness or tenderness near the biopsy site. This soreness
usually disappears within 24-48 hours. Like any minor surgical
procedure, there are certain risks that I am aware of. These include
the risk of infection and the development of a hematoma. The
following precautionswillbe taken to minimize these risks:
1) The biopsieswillbe performed by a physician using
sterile techniques.
2)Iwillbe given directions as to how to care for the
incision. I understand that I must follow these
instructions to minimize the above risks.
3)Iwillperiodically examine the incision and
immediately report any unusual response to the
principal investigator.
4.Benefits to be expected from the research. It is expected that the results
from this researchwillimprove our understanding of muscle function in
MS. My participation may thereby contribute to improving the health
and quality of life for myself and/or others. Iwillalso benefit by
learning about my muscular strength, power, and fatigability and the
muscle fiber type composition of my thigh muscle (% slow and % fast
fibers).
E. Confidentiality. Any information collected from mewillbe kept confidential.
The only persons whowillhave access to this information will be the
investigators. A code numberwillbe used to identify test results or other
information provided by the investigators. My name will never be used in any
data summaries or publications.
F. Corniensation for injury. I understand that the University does not provide a
research subject with compensation or medical treatment in the event that the
subject is injured as a result of participation in the research project.75
G. Voluntary participation statement. I understand that my participation in this
study is completely voluntary and that I may either refuse to participate or
withdraw from the study at any time without penalty or loss of benefits to
which I am otherwise entitled.
H. If! have questions. I understand that any questions I have about the research
study andlor specific procedures should be directed to Jeffrey Widrick, 105
Women's Bldg., Oregon State University, (541) 737-5923. If! have questions
about my rights as a research subject, I should contact the IRB Coordinator,
OSU Research Office, (541) 737- 8008.
I.Understanding and compliance. My signature below indicates that I have read
and I understand the procedures described above and give my informed and
voluntary consent to participate in this study. I understand that Iwillreceive a
signed copy of tbis consent form.
Signature of subject
Date signed
Subjects present address
Signature of Principal Investigator
Name of subject
Subjects phone number
Date signedAPPENDIX B
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Report of Review by the Institutional Review Board for the
Protection of Human Subjects
TO: Jeffiey Widrick, ExSS
COPY:Dena Garner, ExSS
RE: Cellular mechanisms of muscle contraction in individuals with multiple sclerosis.
The referenced project was reviewed under the guidelines of Oregon State University's
Committee for the Protection of Human Subjects and the U.S. Department of Health and Human
Services. The committee has approved your application. The approval of this application
expires upon the completion of the project or one year from the approval date, whichever is
sooner. The informed consent form obtained from each subject should be retained in
program/project's files for three years beyond the end date of the project.
Any proposed change to the protocol or informed consent form that is not included in the
approved application must be submitted to the IRB for review and must be approved by the
committee before it can be implemented. Immediate action may be taken where necessaiy to
eliminate apparent hazards to subjects, but this modification to the approved project must be
reported immediately to the IRB.
Date:/7/
Warren N. Suzuki, Chair
Committee for the Protection of Human Subjects
(Education, 7-6393, suzukiw@orst.edu)